Acquired Immunodeficiency Syndrome (AIDS) Market Anticipated To Witness Robust Growth, Surpassing 41.57 Billion By 2029

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Current Acquired Immunodeficiency Syndrome (AIDS) Market Size and Its Estimated Growth Rate?
The market size for acquired immunodeficiency syndrome (AIDS) has witnessed robust growth in the past few years. It is projected to expand from $32.09 billion in 2024 to $33.85 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.5%. The growth experienced during the historic period can be credited to the escalation in HIV infection rates, amplified government funding allocated for HIV treatments, expansion of worldwide awareness initiatives, enhancements in diagnostic abilities, along with increased backing from non-governmental organizations.

The market for Acquired Immunodeficiency Syndrome (AIDS) is anticipated to experience solid growth in the upcoming years, expanding to a value of $41.57 billion by 2029, representing a compound annual growth rate (CAGR) of 5.3%. The projected growth throughout the forecast period can be credited to a rising requirement for long-acting injectable treatments, heightened uptake of pre-exposure prophylaxis (PrEP), increased funding in curing HIV, the spread of telemedicine services for HIV attention, a heightened emphasis on personalized treatment, and raised consciousness about early HIV diagnosis. Noteworthy trends throughout the forecasted duration will be a shift towards single-tablet programs, a growing penchant for injectable and implantable HIV cures, burgeoning demand for digital health approaches in HIV management, a growing interest in functional HIV cure tactics, and the burgeoning role of artificial intelligence in discovering drugs.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21076

How Are Emerging Segments Shaping the Acquired Immunodeficiency Syndrome (AIDS) Market Landscape?
The acquired immunodeficiency syndrome (AIDS) market covered in this report is segmented -

1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2
2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis
3) By Route Of Administration: Oral, Parenteral
4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications
5) By Distribution Channel: Offline, Online

Subsegments:
1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management
2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp

Which Growth Factors Are Influencing Acquired Immunodeficiency Syndrome (AIDS) Market Expansion?
The acquired immunodeficiency syndrome (AIDS) market is projected to expand due to the rising incidences of HIV infections. HIV, or human immunodeficiency virus, compromises the immune system, leading to a reduced capacity to combat diseases and infections. Unprotected sexual intercourse with an HIV-positive individual, using common needles or syringes, blood transfusion from infected patients, engaging in sexual activities with multiple partners, and having a compromised immune system or other sexual infections are the main causes leading to a surge in HIV cases. By encouraging early identification, broadening the use of efficient antiretroviral therapies, strengthening preventive measures and healTH*Care systems, acquired immunodeficiency syndrome (AIDS) management aids in controlling the spread of this virus more efficiently. For example, data released by the Sweden-based European Centre for Disease Prevention and Control (ECDC), a European Union agency, in November 2024 showed that a total of 112,883 HIV cases were documented across 47 of the 53 nations in the region in 2023. The European Union/European Economic Area (EU/EEA) accounted for 24,731 of these cases. The overall crude rate of HIV diagnoses rose to 12.7 per 100,000 individuals, signifying a 2.4% upsurge compared to the rate of 12.4 per 100, 000 noticed in 2022. It's clear, then, that the surge in HIV cases is a driving force behind the growth of the acquired immunodeficiency syndrome (AIDS) market.

Who Are the Dominant Players Across Different Acquired Immunodeficiency Syndrome (AIDS) Market Segments?
Major companies operating in the acquired immunodeficiency syndrome (AIDS) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy's Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV HealTH*Care

What Are the Latest Developing Trends in the Acquired Immunodeficiency Syndrome (AIDS) Market?
Leading firms in the acquired immunodeficiency syndrome (AIDS) market are prioritizing the development of innovative treatments such as long-acting injectables. These new therapies offer an improvement in patient compliance, decrease the need for frequent dosing, and present a more accessible substitute to daily oral antiretroviral medications. Long-acting injectables works by gradually releasing their active components over a sustained period through an injection, making them require less frequent administration than traditional oral drugs. For example, in January 2025, UK-based pharmaceutical company GSK plc., received endorsement from the European Commission for their long-acting injectable treatment, Vocabria (cabotegravir) plus Rekambys (rilpivirine). Approved for use in adolescents aged 12 years and above living with HIV, it is given via intramuscular injection, usually once or twice a month based on the specific treatment protocol. The extended effectiveness of these injections could potentially enhance adherence rates amongst teens who find it difficult to stick to daily pill routines.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/acquired-immunodeficiency-syndrome-aids-global-market-report

Which Geographic Regions Are Expected to Dominate the Acquired Immunodeficiency Syndrome (AIDS) Market in the Coming Years?
North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (AIDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Acquired Immunodeficiency Syndrome (AIDS) Market?
2. What is the CAGR expected in the Acquired Immunodeficiency Syndrome (AIDS) Market?
3. What Are the Key Innovations Transforming the Acquired Immunodeficiency Syndrome (AIDS) Industry?
4. Which Region Is Leading the Acquired Immunodeficiency Syndrome (AIDS) Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.